660
Views
17
CrossRef citations to date
0
Altmetric
Diabetes

Understanding bolus insulin dose timing: the characteristics and experiences of people with diabetes who take bolus insulin

, , , , , & show all
Pages 639-645 | Received 30 Sep 2016, Accepted 14 Dec 2016, Published online: 24 Jan 2017

References

  • American Diabetes Association. Standards of medical care in diabetes – 2014. Diabetes Care 2014;37:S14-S80
  • Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2012;55:1577-96
  • Handelsman Y, Bloomgarden ZT, Grunberger G, et al. American Association of Clinical Endocrinologists and American College of Endocrinology – clinical practice guidelines for developing a diabetes mellitus comprehensive care plan – 2015 – executive summary. Endocr Pract 2015;21:413-37
  • Monnier L, Colette C. Addition of rapid-acting insulin to basal insulin therapy in type 2 diabetes: indications and modalities. Diabetes Metab 2006;32:7-13
  • Freeman JS. Insulin analog therapy: improving the match with physiologic insulin secretion. J Am Osteopath Assoc 2009;109:26-36
  • Tanaka M, Itoh H. Management of diabetes mellitus with insulin lispro. Clin Med Insights Therapeutics 2011;3:275-89
  • European Medicines Agency. EPAR product information. Apidra 100 Units/ml solution for injection in a vial. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000557/WC500025250.pdf [Last accessed July 2016]
  • European Medicines Agency. EPAR product information. NovoRapid 100 units/ml solution for injection. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000258/WC500030372.pdf [Last accessed July 2016]
  • European Medicines Agency. EPAR product information. Humalog 100 U/ml, solution for injection in vial. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000088/WC500050332.pdf [Last accessed July 2016]
  • Brunner GA, Hirschberger S, Sendlhofer G, et al. Post-prandial administration of the insulin analogue insulin aspart in patients with type 1 diabetes mellitus. Diabet Med 2000;17:371-5
  • Danne T, Aman J, Schober E, et al. A comparison of postprandial and preprandial administration of insulin aspart in children and adolescents with type 1 diabetes. Diabetes Care 2003;26:2359-64
  • Ratner R, Wynne A, Nakhle S, et al. Influence of preprandial vs. postprandial insulin glulisine on weight and glycaemic control in patients initiating basal–bolus regimen for type 2 diabetes: a multicenter, randomized, parallel, open-label study (NCT00135096). Diabetes Obes Metab 2011;13:1142-8
  • Jovanovic L, Giammattei J, Acquistapace M, et al. Efficacy comparison between preprandial and postprandial insulin aspart administration with dose adjustment for unpredictable meal size. Clin Ther 2004;26:1492-7
  • Rave K, Klein O, Frick AD, et al. Advantage of premeal-injected insulin glulisine compared with regular human insulin in subjects with type 1 diabetes. Diabetes Care 2006;29:1812-17
  • Schernthaner G, Wein W, Sandholzer K, et al. Postprandial insulin lispro: a new therapeutic option for type 1 diabetic patients. Diabetes Care 1998;21:570-3
  • Brod M, Nikolajsen A, Weatherall J, et al. Understanding post-prandial hyperglycemia in patients with type 1 and type 2 diabetes: a web-based survey in Germany, the UK, and USA. Diabetes Ther 2016;7:335-48
  • Brod M, Nikolajsen A, Weatherall J, Pfeiffer KM. The economic burden of post-prandial hyperglycemia (PPH) among people with type 1 and type 2 diabetes in three countries. Diabetes Ther 2016;7:75-90
  • Lawton JD, Rankin D, Cooke D, et al. Patients’ experiences of adjusting insulin doses when implementing flexible intensive insulin therapy: a longitudinal, qualitative investigation. Diabetes Res Clin Pract 2012;98:236-42
  • Brunisholz KD, Briot P, Hamilton S, et al. Diabetes self-management education improves quality of care and clinical outcomes determined by a diabetes bundle measure. J Multidiscip Healthc 2014;7:533-42
  • Norris SL, Lau J, Smith SJ, et al. Self-management education for adults with type 2 diabetes: a meta-analysis of the effect on glycemic control. Diabetes Care 2002;25:1159-71
  • Steinsbekk A, Rygg LØ, Lisulo M, et al. Group based diabetes self-management education compared to routine treatment for people with type 2 diabetes mellitus. A systematic review with meta-analysis. BMC Health Serv Res 2012;12:213
  • Weaver RG, Hemmelgarn BR, Rabi DM, et al. Association between participation in a brief diabetes education programme and glycaemic control in adults with newly diagnosed diabetes. Diabet Med 2014;31:1610-14

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.